The stock of Nuwellis Inc. (NASDAQ:NUWE) last traded at $0.12, up 15.61% from the previous session.
Data from the available sources indicates that Nuwellis Inc. (NASDAQ:NUWE) is covered by 3 analysts. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $3.00 and a low of $0.75, we find $2.75. Given the previous closing price of $0.11, this indicates a potential upside of 2400.0 percent. NUWE stock price is now -67.01% away from the 50-day moving average and -81.88% away from the 200-day moving average. The market capitalization of the company currently stands at $4.16M.
In total, 0 analysts have assigned it a hold rating, and 3 have given it a buy rating. Brokers who have rated the stock have averaged $2.17 as their price target over the next twelve months.
A total of 8.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NUWE stock. A new stake in Nuwellis Inc. shares was purchased by TWO SIGMA INVESTMENTS, LP during the first quarter worth $12,000. MILLENNIUM MANAGEMENT LLC invested $5,000 in shares of NUWE during the first quarter. In the first quarter, VIRTU FINANCIAL LLC acquired a new stake in Nuwellis Inc. valued at approximately $4,000. UBS GROUP AG acquired a new stake in NUWE for approximately $2,000. In total, there are 11 active investors with 3.60% ownership of the company’s stock.
With an opening price of $0.1100 on Tuesday morning, Nuwellis Inc. (NASDAQ: NUWE) set off the trading day. During the past 12 months, Nuwellis Inc. has had a low of $0.10 and a high of $1.85. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.60, and a quick ratio of 3.70. The fifty day moving average price for NUWE is $0.3754 and a two-hundred day moving average price translates $0.6827 for the stock.
The latest earnings results from Nuwellis Inc. (NASDAQ: NUWE) was released for Jun, 2022. According to the Medical Devices Company, earnings per share came in at -$0.41, beating analysts’ expectations of -$0.43 by 0.02. This compares to -$0.74 EPS in the same period last year. The company reported revenue of $2.06 million for the quarter, compared to $1.85 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 11.44 percent. For the current quarter, analysts expect NUWE to generate $2.28M in revenue.
Nuwellis Inc.(NUWE) Company Profile
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company’s products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.